Physician

Harmeet Singh, M.D.

According to 2025 Medicare claims, Harmeet Singh, M.D. (NPI: 1306866967) practices nephrology in the Burlington, NC market, with the plurality of this provider's patient population coming from Alamance, NC. This provider's primary affiliated billing organization is CENTRAL CAROLINA KIDNEY ASSOCIATES PA (NPI: 1356582506; TIN: 264116711) and primary practice location at 27253-3763. Singh is affiliated with the Triad HealthCare Network, LLC. (ACO ID: D0209), participating under the REACH model.

Singh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 280 traditional Medicare patients, billed 1,324 HCPCS/CPT codes, and received $132,258 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,736 prescription claims across 452 beneficiaries totaling $306,087 in drug costs, led by Farxiga (Dapagliflozin Propanediol). 2018 DME data shows 36 claims. Open Payments data shows 17 records totaling $367. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $208,293 to $132,258. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $265,489 and ending at $306,087. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	423	2,110	$208,293
2016	385	1,884	$197,234
2017	411	2,111	$226,448
2018	376	1,825	$222,731
2019	366	1,744	$204,678
2020	426	1,732	$217,397
2021	345	1,472	$228,302
2022	268	1,144	$170,456
2023	345	1,224	$159,000
2024	280	1,324	$132,258

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	207	1,762	$265,489
2016	208	1,914	$345,466
2017	213	1,798	$266,012
2018	221	1,877	$84,362
2019	258	1,713	$113,062
2020	272	1,567	$78,359
2021	257	1,517	$52,457
2022	254	1,392	$86,153
2023	372	1,764	$218,082
2024	452	2,736	$306,087

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	36	$1,917
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	39	241	$249
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	137	254	$81
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	56	201	$58
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	55	69	$49
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	157	306	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	221	9,050	$169,956
Jardiance	Empagliflozin	79	2,896	$56,031
Lokelma	Sodium Zirconium Cyclosilicate	15	558	$13,442
Veltassa	Patiromer Calcium Sorbitex	15	430	$7,607
Torsemide	Torsemide	247	14,741	$3,945

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$367	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Harmeet Singh, M.D.?

Tedicare shows public-source Medicare data for Harmeet Singh, M.D. (NPI 1306866967), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Harmeet Singh, M.D. have ACO affiliation data?

Harmeet Singh, M.D. is shown with ACO affiliation data for Triad HealthCare Network, LLC. (REACH, ACO ID D0209).

What billing organization is linked to Harmeet Singh, M.D.?

Harmeet Singh, M.D. is linked to CENTRAL CAROLINA KIDNEY ASSOCIATES PA (billing NPI 1356582506) in the available physician profile data.

Does Harmeet Singh, M.D. have Open Payments data?

Harmeet Singh, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.